CLDN18 and neoplasm: In total, 18 (58.1%) patients with grade 1 tumor differentiation showed positive CLDN18 expression, whereas only 23 (23.2%) patients with grade 2–3 tumor differentiation showed positive CLDN18 expression (p < 0.001).